EA202092727A1 - Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока - Google Patents
Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шокаInfo
- Publication number
- EA202092727A1 EA202092727A1 EA202092727A EA202092727A EA202092727A1 EA 202092727 A1 EA202092727 A1 EA 202092727A1 EA 202092727 A EA202092727 A EA 202092727A EA 202092727 A EA202092727 A EA 202092727A EA 202092727 A1 EA202092727 A1 EA 202092727A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- modified sugar
- biarylamides
- treatment
- heat shock
- diseases associated
- Prior art date
Links
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 229960000956 coumarin Drugs 0.000 abstract 1
- 235000001671 coumarin Nutrition 0.000 abstract 1
- 150000004775 coumarins Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671047P | 2018-05-14 | 2018-05-14 | |
| PCT/US2019/032292 WO2019222269A1 (en) | 2018-05-14 | 2019-05-14 | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092727A1 true EA202092727A1 (ru) | 2021-04-20 |
Family
ID=67002352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092727A EA202092727A1 (ru) | 2018-05-14 | 2019-05-14 | Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11827664B2 (https=) |
| EP (1) | EP3794009A1 (https=) |
| JP (2) | JP7508375B2 (https=) |
| KR (1) | KR20210021457A (https=) |
| CN (2) | CN119285591A (https=) |
| AU (2) | AU2019271126B2 (https=) |
| BR (1) | BR112020023277A2 (https=) |
| CA (1) | CA3100333A1 (https=) |
| CL (1) | CL2020002957A1 (https=) |
| CO (1) | CO2020015380A2 (https=) |
| EA (1) | EA202092727A1 (https=) |
| IL (2) | IL278698B2 (https=) |
| MX (2) | MX2020012366A (https=) |
| PE (1) | PE20211917A1 (https=) |
| PH (1) | PH12020551941A1 (https=) |
| SG (1) | SG11202011311YA (https=) |
| UA (1) | UA130486C2 (https=) |
| WO (1) | WO2019222269A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| EP3793565B1 (en) | 2018-05-14 | 2022-01-05 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN114787139B (zh) | 2019-11-26 | 2025-03-11 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
| EP4247783A1 (en) | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| WO2023039293A1 (en) * | 2021-09-13 | 2023-03-16 | Rubedo Life Sciences, Inc. | Coumarin derivatives of sugar analogs and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2091171A1 (en) | 1990-09-07 | 1992-03-08 | Adriano Afonso | Antiviral compounds |
| DE19512886A1 (de) | 1995-04-06 | 1996-10-10 | Bayer Ag | Substituierte Cycloalkene |
| FR2792320B1 (fr) | 1999-04-19 | 2003-05-09 | Hoechst Marion Roussel Inc | Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments |
| AU2002223127A1 (en) | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| CA2456281A1 (en) | 2001-09-21 | 2003-04-03 | Novartis Ag | Pyrane derivatives as both ace- and nep- inhibitors |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| WO2006050501A2 (en) | 2004-11-03 | 2006-05-11 | University Of Kansas | Novobiocin analogues as anticancer agents |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| WO2008061108A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Phthalazine derivatives |
| DE102007002715A1 (de) * | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
| JP5401329B2 (ja) | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| FR2928645A1 (fr) | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US20100022635A1 (en) | 2008-07-28 | 2010-01-28 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| JP5766617B2 (ja) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US20110082098A1 (en) | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| ES2647889T3 (es) | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| US9056104B2 (en) | 2011-05-20 | 2015-06-16 | The University Of Kansas | Dynamic inhibitors of heat shock protein 90 |
| WO2013112548A1 (en) | 2012-01-23 | 2013-08-01 | University Of South Florida | Gamma-aapeptides with potent and broad-spectrum antimicrobial activity |
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| US9422230B2 (en) | 2013-05-09 | 2016-08-23 | Council Of Scientific And Industrial Research | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride |
| AU2014346483B2 (en) | 2013-11-07 | 2019-01-17 | The University Of Kansas | Biphenylamide derivative Hsp90 inhibitors |
| CA2929243C (en) | 2013-11-11 | 2022-05-03 | The University Of Kansas | Coumarin based hsp90 inhibitors with urea and ether substituents |
| CA2951270C (en) | 2014-06-13 | 2023-07-04 | The University Of Kansas | Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors |
| MX388516B (es) * | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
-
2019
- 2019-05-14 JP JP2020564427A patent/JP7508375B2/ja active Active
- 2019-05-14 CA CA3100333A patent/CA3100333A1/en active Pending
- 2019-05-14 EA EA202092727A patent/EA202092727A1/ru unknown
- 2019-05-14 EP EP19732770.3A patent/EP3794009A1/en active Pending
- 2019-05-14 KR KR1020207033977A patent/KR20210021457A/ko active Pending
- 2019-05-14 SG SG11202011311YA patent/SG11202011311YA/en unknown
- 2019-05-14 IL IL278698A patent/IL278698B2/en unknown
- 2019-05-14 PE PE2020001859A patent/PE20211917A1/es unknown
- 2019-05-14 WO PCT/US2019/032292 patent/WO2019222269A1/en not_active Ceased
- 2019-05-14 AU AU2019271126A patent/AU2019271126B2/en active Active
- 2019-05-14 IL IL309891A patent/IL309891B2/en unknown
- 2019-05-14 CN CN202411057163.3A patent/CN119285591A/zh active Pending
- 2019-05-14 MX MX2020012366A patent/MX2020012366A/es unknown
- 2019-05-14 US US17/055,331 patent/US11827664B2/en active Active
- 2019-05-14 MX MX2025007723A patent/MX2025007723A/es unknown
- 2019-05-14 BR BR112020023277-7A patent/BR112020023277A2/pt unknown
- 2019-05-14 UA UAA202007914A patent/UA130486C2/uk unknown
- 2019-05-14 CN CN201980046311.2A patent/CN112513058B/zh active Active
-
2020
- 2020-11-13 PH PH12020551941A patent/PH12020551941A1/en unknown
- 2020-11-13 CL CL2020002957A patent/CL2020002957A1/es unknown
- 2020-12-09 CO CONC2020/0015380A patent/CO2020015380A2/es unknown
-
2023
- 2023-10-12 US US18/485,699 patent/US12595278B2/en active Active
-
2024
- 2024-06-19 JP JP2024098452A patent/JP2024125338A/ja active Pending
- 2024-11-29 AU AU2024267017A patent/AU2024267017A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020012366A (es) | 2021-02-09 |
| CN119285591A (zh) | 2025-01-10 |
| CO2020015380A2 (es) | 2020-12-21 |
| US20210261592A1 (en) | 2021-08-26 |
| IL278698A (https=) | 2021-01-31 |
| JP7508375B2 (ja) | 2024-07-01 |
| EP3794009A1 (en) | 2021-03-24 |
| UA130486C2 (uk) | 2026-03-04 |
| JP2021524439A (ja) | 2021-09-13 |
| AU2024267017A1 (en) | 2024-12-19 |
| SG11202011311YA (en) | 2020-12-30 |
| PH12020551941A1 (en) | 2021-08-16 |
| IL309891B1 (en) | 2024-11-01 |
| CA3100333A1 (en) | 2019-11-21 |
| IL309891A (en) | 2024-03-01 |
| US12595278B2 (en) | 2026-04-07 |
| IL278698B1 (en) | 2024-02-01 |
| KR20210021457A (ko) | 2021-02-26 |
| US20240182507A1 (en) | 2024-06-06 |
| AU2019271126B2 (en) | 2024-08-29 |
| BR112020023277A2 (pt) | 2021-02-23 |
| IL278698B2 (en) | 2024-06-01 |
| IL309891B2 (en) | 2025-03-01 |
| WO2019222269A1 (en) | 2019-11-21 |
| CL2020002957A1 (es) | 2021-04-16 |
| CN112513058A (zh) | 2021-03-16 |
| US11827664B2 (en) | 2023-11-28 |
| CN112513058B (zh) | 2024-08-20 |
| AU2019271126A1 (en) | 2020-12-10 |
| JP2024125338A (ja) | 2024-09-18 |
| MX2025007723A (es) | 2025-08-01 |
| PE20211917A1 (es) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092727A1 (ru) | Биариламиды с модифицированными сахарными группами для лечения заболеваний, связанных с путем белка теплового шока | |
| EA202192888A1 (ru) | Соединения и способы нацеливания на тау человека | |
| EA202090555A1 (ru) | Фармацевтические композиции, содержащие антитела к бета-амилоиду | |
| EA201891676A1 (ru) | Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения | |
| JOP20190193B1 (ar) | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
| MA40378B1 (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| ZA201901168B (en) | Novel compounds for treating parasitic disease | |
| EP4427815A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| EA201791367A1 (ru) | Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EA202092305A1 (ru) | Соединения в качестве модуляторов сигнализации tlr2 | |
| CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| PH12019502096A1 (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| BR112022021743A2 (pt) | Compostos e métodos direcionando a interleucina-34 | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| BR112017007095A2 (pt) | conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular | |
| BR112021019110A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| JOP20210009A1 (ar) | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease |